UCB, a Belgian biopharmaceutical company, has announced the divestment of its mature neurology and allergy portfolio in China for $680 million, marking a strategic shift towards innovation and partnerships in one of the world’s fastest-growing pharmaceutical markets. This significant deal involves the sale of well-known products such as Keppra, Vimpat, Neupro, Zyrtec, and Xyzal, along […]
AN2 Therapeutics, Inc., a pioneering force in novel small molecule drugs, has announced a dramatic reduction of its workforce by approximately 50%. This decision follows the discontinuation of its phase 3 clinical trial for epetraborole in treating refractory MAC lung disease, which did not meet several key secondary endpoints. As of late February, AN2 Therapeutics […]
Antengene Corporation Limited, a commercial-stage global biopharmaceutical company, has announced a significant milestone with the China National Medical Products Administration (NMPA) approving a new indication for XPOVIO (selinexor). This approval allows the use of XPOVIO as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), one of the most […]
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a notable player in the biopharmaceutical sector, has made a significant announcement that could have wide-reaching implications for kidney transplant recipients. The company revealed its plans to submit an Investigational New Drug (IND) application for CID-103 to the U.S. Food and Drug Administration (FDA) by the end of 2024. CID-103, […]
In a significant move to enhance its immunology offerings, Johnson & Johnson (NYSE: JNJ) has announced a definitive agreement to acquire a wholly-owned subsidiary of Numab Therapeutics, gaining global rights to an investigational bispecific antibody, NM26. The deal, valued at approximately $1.25 billion, is poised to transform treatment paradigms in atopic dermatitis (AD) and potentially […]
In a landmark announcement, Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and a subsidiary of Biocon Ltd, revealed its settlement and license agreement with Janssen Biotech Inc., and Johnson & Johnson. This agreement signifies a crucial step forward, granting Biocon Biologics the license to commercialize its Bmab 1200, a proposed biosimilar to […]